155
Participants
Start Date
December 31, 2018
Primary Completion Date
June 4, 2020
Study Completion Date
June 4, 2020
DAXI 80 U
DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
DAXI 120 U
DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
Placebo
Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
LA Podiatry Group, West Palm Beach
Rosalind Franklin University of Medicine & Science, North Chicago
Podiatry 1st, Belleville
Medical Research International, Oklahoma City
North Texas Institute of Neurology and Headache, Frisco
Hermann Drive Research Hospital, Houston
Strash Foot and Ankle Care, San Antonio
The Podiatry Group of South Texas, San Antonio
Futuro Clinical Trials, LLC, McAllen
Rocky Mountain Foot and Ankle, LLC, Salt Lake City
Wasatch Clinical Research, Salt Lake City
Aung Foot Health Clinic, Tucson
Advanced Foot & Ankle Center, Las Vegas
Foot and Ankle Clinic, Los Angeles
University Foot and Ankle Foundation, Santa Monica
West Coast Foot and Ankle, Huntington Beach
Bay Area Foot Care, San Francisco
Bay Area Foot Care, Castro Valley
Sacramento Foot and Ankle Center, Inc, Carmichael
Kansas Institute of Research, Overland Park
Revance Therapeutics, Inc.
INDUSTRY